NAIROBI, KENYA — Researchers in Kenya have identified Africa’s first recorded case of a fungus resistant to drugs across all four major classes of antifungal medicine. The pan-drug-resistant (PDR) organism, Candidozyma auris (formerly Candida auris), was isolated from a 28-year-old surgical patient treated at a tertiary hospital in Nairobi over an eight-month period.
Published in Scientific Reports, the study by the Kenya Medical Research Institute (KEMRI) warns that a fungus resistant to drugs on this scale is exceedingly rare globally, with only one previous case recorded in New York in 2022.
Lab Tests Confirm a Superbug Fungus Resistant to Drugs
Laboratory testing demonstrated that the isolated C. auris strain is a superbug fungus resistant to all drugs spanning every primary antifungal class:
The emergence of a fungus resistant to all drugs presents severe clinical and operational challenges within hospital environments, particularly for vulnerable ICU patients:
High Mortality Rate: The World Health Organization (WHO) estimates that 30 to 53 percent of patients with invasive C. auris infections die.
Environmental Persistence: The yeast survives on medical equipment and surfaces for long periods, driving rapid transmission across hospital wards.
Diagnostic Gaps: Most African laboratories lack the specialized equipment needed to identify fungal species or test which medications remain effective.
Stopping the Spread of a Fungus Resistant to Drugs
Because no effective antifungal medication remains for this strain, strict infection control is the primary defense against it :
Rapid Carrier Isolation: Immediate screening and isolation of suspected hospital patients.
Surface Disinfection: Deep cleaning rooms and equipment with specialized EPA-registered disinfectants.
Strict Hand Hygiene: Enforcing rigorous hand hygiene protocols among surgical and ICU healthcare workers.
Antimicrobial resistance (AMR) causes over one million bacterial deaths globally each year, including 6,670 AMR-related deaths recorded in Kenya in 2021. Health experts warn that while bacterial resistance receives significant attention, fungal resistance remains dangerously under-monitored.
Why It Matters: A hospital-acquired fungus that resists every standard drug leaves doctors with zero treatment options, making strict infection control and early surveillance the only line of defense for surgical patients.
Understanding and Managing Common Fungal Infections:… Fungal infections, though often overlooked, are common health concerns that can affect various parts of the body. From the irritating itch of athlete's foot to the discomfort of a yeast infection, understanding these infections is…
Combining Painkillers with Hormonal Birth Control… In recent findings, commonly used pain relievers, including ibuprofen, diclofenac, and naproxen, have been associated with an increased risk of venous thromboembolism (VTE), a potentially life-threatening blood clot that can form deep within a vein,…
Voriconazole: Uses, Dosage, Side Effects and Safety… Treating serious, systemic fungal infections requires potent targeted medication and careful clinical oversight. This essential Voriconazole antifungal therapy guide details how this triazole antifungal works, correct administration timing around meals, key side effect management, and…
Kenya Discharges Five Ebola Patients, Africa CDC… NAIROBI, KENYA — Kenya Ebola patients discharged on Tuesday included five people who had recorded repeated negative tests, while 46 contacts completed their 21-day quarantine, the Africa Centres for Disease Control and Prevention (Africa…
